Abstract
Under physiological circumstances, cellular responses often reflect integration of signaling by two or more different receptors activated coincidentally or sequentially. In addition to heterologous desensitization, there are examples in which receptor activation either reveals or potentiates signaling by a different receptor type, although this is perhaps less well explored. Here, we characterize one such interaction between endogenous receptors in human embryonic kidney 293 cells in which Galpha(q/11)-coupled muscarinic M(3) receptors facilitate Ca(2+) signaling by Galpha(s)-coupled beta(2)-adrenoceptors. Measurement of changes in intracellular [Ca(2+)] demonstrated that noradrenaline released Ca(2+) from thapsigargin-sensitive intracellular stores only during activation of muscarinic receptors. Agonists with low efficacy for muscarinic receptor-mediated Ca(2+) responses facilitated cross-talk more effectively than full agonists. The cross-talk required Galpha(s) and was dependent upon intracellular Ca(2+) release channels, particularly inositol (1,4,5)-trisphosphate receptors. However, beta(2)-adrenoceptor-mediated Ca(2+) release was independent of measurable increases in phospholipase C activity and resistant to inhibitors of protein kinases A and C. Interestingly, single-cell imaging demonstrated that particularly lower concentrations of muscarinic receptor agonists facilitated marked oscillatory Ca(2+) signaling to noradrenaline. Thus, activation of muscarinic M(3) receptors profoundly influences the magnitude and oscillatory behavior of intracellular Ca(2+) signaling by beta(2)-adrenoceptors. Although these receptor subtypes are often coexpressed and mediate contrasting acute physiological effects, altered oscillatory Ca(2+) signaling suggests that cross-talk could influence longer term events through, for example, regulating gene transcription.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Pharmacology and Experimental Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.